PERSERIS Drug Insight

“PERSERIS Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about PERSERIS for schizophrenia in the US market. A detailed picture of the PERSERIS for schizophrenia in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the PERSERIS for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PERSERIS market forecast analysis for schizophrenia in the US, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia.

Drug Summary

PERSERIS contains risperidone, a well-established medicine for schizophrenia, and uses an extended-release delivery system to form a subcutaneous (under the skin) depot that provides sustained levels of risperidone over 1 month. It delivers its active ingredient, risperidone, in an extended-release delivery system with no loading doses or oral supplementation recommended. Clinically relevant levels were reached after the first injection of PERSERIS without a loading dose or any supplemental oral risperidone. Initial peak risperidone plasma levels occur within 4–6 h of dosing and are due to an initial drug release during the depot formation process.

Dosage and administration

PERSERIS is to be administered as an abdominal subcutaneous injection only. For patients who have never taken risperidone, establish tolerability with oral risperidone before starting PERSERIS. Initiate PERSERIS at a dose of 90 mg or 120 mg once monthly by subcutaneous injection. Do not administer more than one dose (90 mg or 120 mg total) per month.

Mechanism of action

The mechanism of action of risperidone in schizophrenia is unclear. The therapeutic activity of the drug in schizophrenia could be mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) receptor antagonism. The clinical effect of risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone (paliperidone). Antagonism at receptors other than D2 and 5HT2 may explain the other effects of risperidone.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the PERSERIS description, mechanism of action, dosage and administration, research and development activities in schizophrenia.
• Elaborated details on PERSERIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PERSERIS research and development activities in schizophrenia across the United States.
• The report also covers the patents information with expiry timeline around PERSERIS.
• The report contains forecasted sales of for schizophrenia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for schizophrenia.
• The report also features the SWOT analysis with analyst views for PERSERIS in schizophrenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PERSERIS Analytical Perspective by DelveInsight

• In-depth PERSERIS Market Assessment

This report provides a detailed market assessment of PERSERIS for schizophrenia in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

• PERSERIS Clinical Assessment

The report provides the clinical trials information of PERSERIS for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PERSERIS dominance.
• Other emerging products for schizophrenia are expected to give tough market competition to PERSERIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PERSERIS in schizophrenia.
• Our in-depth analysis of the forecasted sales data of PERSERIS from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PERSERIS in schizophrenia.

Key Questions

• What is the product type, route of administration and mechanism of action of PERSERIS?
• What is the clinical trial status of the study related to PERSERIS in schizophrenia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PERSERIS development?
• What are the key designations that have been granted to PERSERIS for schizophrenia?
• What is the forecasted market scenario of PERSERIS for schizophrenia?
• What are the forecasted sales of PERSERIS in the United States? 
• What are the other emerging products available and how are these giving competition to PERSERIS for schizophrenia?
• Which are the late-stage emerging therapies under development for the treatment of schizophrenia?